Skip to main
CME

CME Group (CME) Stock Forecast & Price Target

CME Group (CME) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 33%
Hold 33%
Sell 8%
Strong Sell 0%

Bulls say

CME Group is well positioned for continued growth and success in its industry, with a strong and established position in the global market and a diversification of products to appeal to a variety of customer needs. The company's recent strategic acquisitions and partnerships show a focus on expanding its offerings and reaching new customers, while its high operating margins and strong cash flow generation provide the ability to return value to shareholders through dividends and potential share buybacks. Additionally, the upcoming launch of a prediction markets app through its partnership with FanDuel has the potential to drive further revenue growth in the future, making CME an attractive investment option.

Bears say

CME Group is facing increased competition, particularly from their main competitor FMX, which could potentially result in moderating trading volume and revenue growth. The recent acquisition of NEX should drive future growth for CME by expanding their product offerings and allowing them to better meet the needs of a broader international customer base. However, in the current market climate with potential pricing pressures and limited margin upside, there are fundamental risks and uncertainties that could impact CME's financial performance. Additionally, while there is potential for upside due to the integration of NEX and the potential growth of sports-related prediction markets, it is uncertain and could take longer to materialize.

CME Group (CME) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CME Group (CME) Forecast

Analysts have given CME Group (CME) a Buy based on their latest research and market trends.

According to 12 analysts, CME Group (CME) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $307.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $307.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CME Group (CME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.